Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19776047 | 0.94 | CASP1 (0.39) | CASP1 | |
| SCHEMBL18272885 | 0.83 | CASP1 (0.41) | CASP1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL27111229 | 0.83 | FAAH (0.45) | CASP1NMT2NMT1FAAHMEN1 | |
| SCHEMBL20349710 | 0.83 | CASP1 (0.41) | CASP1FAAHMEN1MAPK1KMT2A | |
| SCHEMBL20340683 | 0.81 | EPHX2 (0.39) | CASP1FAAH | |
| SCHEMBL24992769 | 0.80 | — | — | |
| SCHEMBL18596603 | 0.78 | PTGS1 (0.43) | CASP1FAAHMAPK1KMT2A | |
| SCHEMBL22267884 | 0.78 | PTGS1 (0.43) | CASP1FAAHMAPK1KMT2A | |
| SCHEMBL18596600 | 0.78 | PTGS1 (0.43) | CASP1FAAHMAPK1KMT2A | |
| SCHEMBL21579982 | 0.78 | PSENEN (0.39) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | CASP1 4384/4885NMT2 152/4885NMT1 337/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | CASP1 4384/4885NMT2 152/4885NMT1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.